Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

This study has been completed.
Information provided by:
Mannkind Corporation Identifier:
First received: January 12, 2007
Last updated: August 2, 2010
Last verified: August 2010
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.

Condition Intervention Phase
Endometrial Carcinoma
Cervical Carcinoma
Testicular Cancer
Thyroid Cancer
Small Cell Lung Carcinoma
Breast Carcinoma
Esophageal Carcinoma
Gastric Cancer
Pancreatic Carcinoma
Neuroendocrine Cancer
Liver Cancer
Gallbladder Cancer
Biliary Tract Cancer
Anal Carcinoma
Bone Sarcomas
Soft Tissue Sarcomas
Carcinoma of Unknown Origin, Primary
Biological: PSMA/PRAME
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies

Resource links provided by NLM:

Further study details as provided by Mannkind Corporation:

Primary Outcome Measures:
  • To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP [ Time Frame: Every 6 Weeks ]

Secondary Outcome Measures:
  • to determine the blood plasmid levels by PCR analysis [ Time Frame: Every 6 Weeks ]
  • measure cytokine levels [ Time Frame: Every 6 Weeks ]
  • to describe any objective tumor responses to the treatment with MKC1106-PP [ Time Frame: Every 6 Weeks ]

Enrollment: 12
Study Start Date: February 2007
Study Completion Date: November 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low Dose Cohort Biological: PSMA/PRAME
Low dose
Experimental: High Dose Cohort Biological: PSMA/PRAME
high dose

Detailed Description:
The majority of tumors are ignored by the immune system and it was thought for a long time that tumor antigens did not exist. However, recently a number of tumor antigens have been described. These antigens reside on cancer cells and can be recognized by specific T-cells which can ultimately attack and destroy the tumor.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

18 years of age or older Advanced, refractory solid malignancy that is histologically proven Measurable disease ECOG performance status of 0, 1 or 2 Adequate bone marrow reserve as evidenced by a Absolute neutrophil count (ANC) = 1,500/microL; Platelet count = 100,000/microL Adequate renal and hepatic function as evidenced by a serum creatinine = 1.5 mg/dL; Serum total bilirubin = 2.0 mg/dL; Alkaline phosphatase = 3X the ULN for the reference lab (= 5 the ULN for the reference lab for subjects with known hepatic metastases); SGOT/SGPT = 3X the ULN for the reference lab (= 5 the ULN for the reference lab for subjects with known hepatic metastases)

Exclusion Criteria:

Symptomatic central nervous system (CNS) metastases Any autoimmune disorder Positive HIV, hepatitis B or hepatitis C antibody test Any allogeneic transplant Congestive heart failure Affected inguinal lymph nodes (metastatic process) or lack inguinal lymph nodes (resection)

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00423254

United States, Arizona
Arizona Cancer Center
Tuscon, Arizona, United States, 85724-5024
United States, District of Columbia
Lombardi Comprehensive Cancer Center at Georgetown
Washington, District of Columbia, United States, 20057
United States, Florida
H Lee Moffitt Cancer Center University of So Florida
Tampa, Florida, United States, 33612
United States, Nevada
Nevada Cancer Institute
Sparks, Nevada, United States, 89431
United States, New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Mannkind Corporation
  More Information

Responsible Party: Mihail Obrocea/Vice President-Oncology - Medical & Regulatory Affairs, MannKind Corporation Identifier: NCT00423254     History of Changes
Other Study ID Numbers: MKC1106-PP-001
Study First Received: January 12, 2007
Last Updated: August 2, 2010

Keywords provided by Mannkind Corporation:
Cancer Vaccine

Additional relevant MeSH terms:
Stomach Neoplasms
Liver Neoplasms
Thyroid Neoplasms
Breast Neoplasms
Lung Neoplasms
Endometrial Neoplasms
Biliary Tract Neoplasms
Gallbladder Neoplasms
Esophageal Neoplasms
Small Cell Lung Carcinoma
Testicular Neoplasms
Pancreatic Neoplasms
Anus Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Liver Diseases
Neoplasms, Mesothelial processed this record on April 25, 2017